Rohto Pharma Raises FY2027 Forecast on Strong Asian, Japanese, European Sales

On August 6, Rohto Pharmaceutical announced an upward revision of its full‑year FY2027 (ending March 2027) consolidated earnings outlook. The company increased its projected revenue to ¥3,723 billion, up from ¥3,695 billion, and raised operating profit to ¥450 billion, up from ¥438 billion. The revision reflects better‑than‑expected performance in the Asia, Japan and Europe segments and a change in foreign‑exchange assumptions, with the yen rate adjusted from ¥155 to ¥158 per dollar and the Chinese yuan rate from ¥22 to ¥23.

The updated guidance implies a 0.8 % rise in sales and a 2.7 % increase in operating profit compared with the prior forecast, while also modestly lifting expected ordinary profit and net profit. Rohto noted that the first‑quarter results exceeded its internal targets, prompting the forecast adjustment.